Design, Pharmacokinetic, and Pharmacodynamic Evaluation of a New Class of Soft Anticholinergics

Pharmaceutical Research

Volumn 20, Issue 10, 2003, Pages 1681-1689

  Huang, Fenglei ^a   Browne, Clinton E ^a   Wu, Whei Mei ^a   Juhász, Attila ^a,b   Ji, Fubao ^a,b   Bodor, Nicholas ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Anticholinergic agents; Metabolism; Muscarinic receptor subtypes; Receptor binding; Soft drugs

Indexed keywords

ATROPINE; CARBACHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; ETHYL 2 [8 AZA 8 METHYL 3 (2 PHENYLCYCLOHEX 2 ENYLCARBONYLOXY)BICYCLO[3.2.1]OCT 8 YL]ACETATE BROMIDE; ETHYL 2 [8 AZA 8 METHYL 3 (2 PHENYLCYCLOHEX 2 ENYLCARBONYLOXY)BICYCLO[3.2.1]OCT 8 YL]ACETATE METHYL HYDROXYSULFONATE; METHYL 2 [8 AZA 8 METHYL 3 (2 PHENYLCYCLOHEX 2 ENYLCARBONYLOXY)BICYCLO[3.2.1]OCT 8 YL]ACETATE BROMIDE; METHYL 2 [8 AZA 8 METHYL 3 (2 PHENYLCYCLOHEX 2 ENYLCARBONYLOXY)BICYCLO[3.2.1]OCT 8 YL]ACETATE METHYL HYDROXYSULFONATE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; RECEPTOR SUBTYPE; TROPICAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFECT; DRUG ELIMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; INTERMETHOD COMPARISON; MALE; MYDRIASIS; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION;

ADMINISTRATION, TOPICAL; ANIMALS; AZA COMPOUNDS; CHOLINERGIC AGENTS; CYCLOHEXANES; DRUG DESIGN; DRUG STABILITY; EYE; HEART RATE; MALE; MYDRIATICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MUSCARINIC; TIME FACTORS;

EID: 0142105935     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026160023030     Document Type: Article

References (58)

1. J. H. Brown and P. Taylor. Muscarinic receptor agonists and antagonists. In L. S. Goodman, A. Gilman, I. G. Hardman, A. G. Gilman, and L. E. Limbird (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 1996, pp. 141-160.
2. A. Gomez, I. Bellido, and F. Sanchez de la Cuesta. Atropine and glycopyrronium show similar binding patterns to M2 (cardiac) and M3 (submandibular gland) muscarinic receptor subtypes in the rat. Br. J. Anaesth. 74:549-552 (1995).
3. R. K. Mirakhur, J. W. Dundee, and R. S. Clarke. Glycopyrrolateneostigmine mixture for antagonism of neuromuscular block: comparison with atropine-neostigmine mixture. Br. J. Anaesth. 49:825-829 (1977).
4. O. Takkunen, M. Salmenpera, and J. Heinonen. Atropine vs glycopyrrolate during reversal of pancuronium block in patients anaesthetized with halothane. Acta Anaesthesiol. Scand. 28:377-380 (1984).
5. J. Wetterslew, I. Jarnvig, N. L. Jorgensen, and N. V. Olsen. Split-dose atropine verse glycopyrrolate with neostigmine for reversal of gallamine-induced neromuscular blockage. Acta. Anaesthesiol Scand. 35:398-401 (1991).
6. F. T. Fraunfelder. Mydriatics and cycloplegics. In Drug-Induced Ocular Side Effects and Drug Interactions, Vol. 3, Lea & Febiger. New York, 1989, pp. 445-458.
7. B. D. Wright. Exacerbation of akinetic seizure by atropine eye drops. Br. J. Ophthamol. 76:179-180 (1992).
8. L. J. Birkhimer, P. A. Jacobson, J. Olson, and D. M. Goyette. Ocular scopolamine induced psychosis. J. Fam. Prac. 18:464-469 (1984).
9. A. K. Khurana, B. K. Ahluwalia, C. Rajan, and A. K. Vohra. Acute psychosis associated with topical cyclopentolate hydrochloride. Am. J. Ophthalmol. 105:91 (1988).
10. D. G. Jayamanne, N. Ray-Chaudhuri, R. Wariyar, and D. G. Cottrell. Haemodynamic responses to subconjunctival mydriatic agents (Mydricaine) used for maintenance of perioperative mydriasis in patients undergoing vitreoretinal surgery. Eye 12:792-794 (1998).
11. G. J. Merli, H. Weitz, J. H. Martin, E. F. McClay, A. G. Adler, F. M. Fellin, and M. Libonati. Cardiac dysrhythmias associated with ophthalmic atropine. Arch. Intern. Med. 146:45-47 (1986).
12. J. P. Diamond. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 11:352-360 (1997).
13. F. S. K. Macmillan, H. Reller, and F. H. T. Synder. The antiperspirant action of topically applied anticholinergics. J. Invest. Dermatol. 42:363-377 (1964).
14. W. B. Shelley and P. N. Horvath. Comparative study on the effect of anticholinergic compounds on sweating. J. Invest. Dermatol 16:267-274 (1951).
15. R. B. Stoughton, F. Chiu, W. Fritsch, and D. Nurse. Topical suppression of eccrine sweat delivery with a new anticholinergic agent. J. Invet. Dermatol. 42:151-155 (1964).
16. A. E. Lasser. Results of a double-blind clinical study of a new anticholinergic agent as an anxillary antiperspirant. Illinois Med. J. March:314-317 (1967).
17. N. Bodor. Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems. In B. Testa (ed), Advance in Drug Research, Vol. 13, Academic Press, Orlando, 1984, pp. 255-331.
18. N. Bodor. Soft Drugs, Encyclopedia of Human Biology, Vol. 7, Academic Press. Orlando, 1990.
19. N. Bodor. Retrometabolic approaches for drug design and targeting. Pharmazie 52:491-494 (1997).
20. N. Bodor and P. Buchwald. Soft drug design: general principles and recent applications. Med. Res. Rev. 20:58-101 (2000).
21. G. Brouillette, M. Kawamura, G. N. Kumar, and N. Bodor. Soft drugs. 21. Design and evaluation of soft analogs of propantheline. J. Pharm. Sci. 85:619-623 (1996).
22. R. H. Hammer, K. Amin, Z. E. Gunes, G. Brouillette, and N. Bodor. Novel "soft" anticholinergic agents. Drug Des. Deliv. 2: 207-219 (1988).
23. G. N. Kumar, R. H. Hammer, and N. S. Bodor. Soft drugs. 12: Design, syntheses and evaluation of soft anticholinergics. Drug Des. Discov. 10:11-21 (1993).
24. G. N. Kumar, R. H. Hammer, and N. S. Bodor. Soft drugs. 13: Design and evaluation of phenylsuccinic analogs of scopolamine as soft anticholinergics. Drug Des. Discov. 10:1-9 (1993).
25. A. Juhasz, F. Huang, F. Ji, P. Buchwald, W. M. Wu, and N. Bodor. Design and evaluation of new soft anticholinergic agents. Drug Dev. Res. 43:117-127 (1998).
26. F. Ji, F. Huang, A. Juhasz, W. Wu, and N. Bodor. Design, synthesis, and pharmacological evaluation of soft glycopyrrolate and its analog. Pharmazie 55:187-191 (2000).
27. M. P. Caulfield. Muscarinic receptors - characterization, coupling and function. Pharmacol. Ther. 58:319-379 (1993).
28. T. I. Bonner, N. J. Buckley, A. C. Young, and M. R. Brann. Identification of a family of muscarinic acetylcholine receptor genes. Science 237:527-532 (1987).
29. T. I. Bonner, A. C. Young, M. R. Brann, and N. J. Buckley. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:40-410 (1988).
30. E. G. Peralta, A. Ashkenazi, J. W. Winslow, D. H. Smith, J. Ramachandran, and D. J. Capon. Distinct primary structures, ligand-binding properties and tissue- specific expression of four human muscarinic acetylcholine receptors. EMBO J. 6:3923-3929 (1987).
31. C. Bolden, B. Cusack, and E. Richelson. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 260:576-580 (1992).
32. N. J. Buckley, T. I. Bonner, C. M. Buckley, and M. R. Brann. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mo. Pharmacol. 35:469-476 (1989).
33. P. Barbier, A. R. Renzetti, L. Turbanti, C. Di Bugno, F. Fornai, F. Vaglini, R. Maggio, and G. U. Corsini. Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine. Eur. J. Pharmacol. 290:125-132 (1995).
34. J. Wess, G. Lambrecht, E. Mutscher, M. R. Brann, and F. Dorje. Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations. Br. J. Pharmacol. 102:246-250 (1991).
35. M. Waelbroeck, S. Lazareno, O. Pfaff, T. Friebe, M. Tastenoy, E. Mutschler, and G. Lambrecht. Stereoselective recognition of the enantiomers of phenglutarimide and of six related compounds by four muscarinic receptor subtypes. Br. J. Pharmacol. 119:1319-1330 (1996).
36. R. M. Eglen and N. Waston. Selective muscarinic receptor agonists and antagonists. Pharmacol. Toxicol. 78:59-68 (1996).
37. U. Grimm, U. Moser, E. Mutschler, and G. Lambrecht. Muscarinic receptors: focus on presynaptic mechanisms and recently developed novel agonists and antagonists. Pharmazie 49:711-726 (1994).
38. F. Huang, P. Buchwald, C. E. Browne, H. H. Farag, W.-M. Wu, F. Ji, G. Hochhaus, and N. Bodor. Receptor binding studies of soft anticholinergic agents. AAPS PharmSci. 3:E30 (2001).
39. S. H. Greenstein and D. H. Abramson, and W. R. D. Pitts. Systemic atropine and glaucoma. Bull. N. Y. Acad. Med. 60:961-968 (1984).
40. S. M. Mostafa and M. Vucevic. Comparison of atropine and glycopyrronium in patients with pre-existing cardiac disease. Anaesthesia 39:1207-1213 (1984).
41. L. Turbanti, G. Cerbai, G. Garzelli, A. R. Renzetti, M. Criscuoli, A. Subissi, G. Bramanti, and A. Martinelli. N-Alkylnortropine esters of 2-phenylcyclohexenic acids as new bronchodilator agents: Effect of structural and conformational modifications on affinity for muscarinic receptors. Eur. J. Med. Chem. 27:449-462 (1992).
42. G. D'Agostino, A. R. Renzetti, F. Zonta, and A. Subissi. Selectivity of LG 50643 for postjunctional muscarinic-receptor subtype in the guinea-pig trachea. J. Pharm. Pharmacol. 46:332-336 (1994).
43. N. Bodor, A. Elkoussi, and R. Hammer. Soft dugs. 9. The ultrashort duration of the muscarinolytic activity of a new short-acting soft mydriatic agents. J. Biopharm. Sci. 3:215-223 (1990).
44. M. Sokolovsky. Muscarinic receptors in the central nervous system. Int. Rev. Neurobiol. 25:139-183 (1984).
45. S. R. Hitchcock, F. Perron, V. A. Martin, and K. F. Albizati. Efficient synthesis of alfa-(hydroxymethyl) ketones not available trough aldol-type processes. Synthesis N11:1059-1061 (1990).
46. H. E. Zimmerman and J. English. J. The cleavage reaction of 1,3-diols. I. J. Am. Chem. Soc. 76:2285-2290 (1954).
47. F. Huang, W.-M. Wu, F. Ji, A. Juhasz, and N. Bodor. Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopeneacetate. Pharmazie 57:115-121 (2002).
48. G. P. Crowther, E. M. Kaizer, R. A. Woodruff, and C. R. Hauser. Esterification of hindered alcohols: tert-butyl-p-toluate. In E. W. Noland (ed.), Organic Syntheses Collective, Vol. 6, John Wiley & Sons, New York, 1988, pp. 259-262.
49. J. B. Key, J. B. Robinson, and J. Thomas. The preparation of some stereospecific tropane and N-alkynortropane derivatives. J. Chem. Soc. 5112-5115 (1965).
50. S. P. Findlay. Stereoisomeric quaternary ammonium derivatives of tropine having a pseudoasymmetric nitrogen atom. J. Amer. Chem. Soc. 75:3024-3028 (1953).
51. M. Koreeda and J. I. Luengo. A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine. J. Org. Chem. 49:2081-2082 (1984).
52. N. Bodor, R. Woods, C. Raper, P. Kearney, and J. J. Kaminski. Soft drugs. 3. A new class of anticholinergic agents. J. Med. Chem. 23:474-480 (1980).
53. G. N. Kumar, R. H. Hammer, and N. Bodor. Soft drugs-XVI. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine. Bioorganic & Med. Chem. 1:327-332 (1993).
54. R. H. Hammer, W.-M. Wu, J. S. Sastry, and N. Bodor. Short acting soft anticholinergics. Curr. Eye Res. 10:565-570 (1991).
55. G. G. Deshpande and R. D. Schoenwald. A comparison of the in vitro and ex vivohydrolysis rates of ethacrynate esters and their relationship to intraoular pressure in the rabbit eye. PharmSci Suppl. 1:s33 (1998).
56. M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, Inc., New York, 1982.
57. N. Bodor, W.-M. Wu, T. Murakami, and S. Engel. Soft drug 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteriod, loteprednol etabonate, in rats. Pharm. Res. 12:876-879 (1995).
58. R. H. Gray. The influence of drop size on pupil dilation. Eye 5:615-619 (1991).